How to Get Vyleesi (Bremelanotide) in District of Columbia

What Is Vyleesi and Who Is It For?

Bremelanotide is a melanocortin-4 receptor agonist that the FDA approved in June 2019 under the brand name Vyleesi for acquired, generalized HSDD in premenopausal women. It is not indicated for postmenopausal HSDD or for enhancing sexual performance in the absence of a clinical diagnosis.

The FDA approval was based on two Phase 3 trials (RECONNECT 1 and RECONNECT 2) enrolling a combined 1,247 premenopausal women with HSDD. In the pooled RECONNECT analysis, bremelanotide 1.75 mg produced a statistically significant increase in the Female Sexual Function Index desire domain score (mean change +0.5 vs. placebo, P<0.001) and a meaningful reduction in distress as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score [1]. About 25% of women on bremelanotide experienced clinically meaningful improvement in desire, compared to roughly 17% on placebo [2].

Unlike flibanserin (Addyi), which requires daily oral dosing, bremelanotide is used on-demand. That pharmacologic distinction matters for women who prefer not to take a daily medication for episodic symptoms.

Telehealth Prescribing in District of Columbia

DC law permits licensed prescribers to evaluate, diagnose, and prescribe medications via telehealth, making bremelanotide accessible without an in-person office visit. A synchronous audio-video consultation satisfies the prescriber-patient relationship requirement under DC telemedicine regulations.

During a telehealth visit for HSDD, expect the clinician to review your symptom history using a validated screening tool such as the Decreased Sexual Desire Screener (DSDS), confirm the diagnosis is acquired and generalized, rule out medication-induced causes (SSRIs, hormonal contraceptives, antihypertensives), and verify you are premenopausal. The entire appointment typically runs 20 to 30 minutes.

The Endocrine Society's clinical practice guidelines recommend a structured assessment that distinguishes HSDD from other sexual dysfunctions before initiating pharmacotherapy [3]. Your prescriber should document that nonpharmacologic strategies (counseling, relationship therapy, lifestyle modification) have been discussed, even if you elect not to pursue them. DC-based telehealth platforms that specialize in women's sexual health can simplify this process, and prescriptions are typically sent electronically to a pharmacy the same day the visit concludes.

Who Can Prescribe Vyleesi in DC?

District of Columbia grants full prescriptive authority to physicians (MD and DO), nurse practitioners, and physician assistants. All three provider types can independently prescribe bremelanotide in the District. NPs in DC practice under full practice authority per the District of Columbia Nurse Practice Act, meaning no collaborative agreement with a physician is required.

This broad scope of practice increases patient access. If your primary care provider is unfamiliar with HSDD management, a women's health NP or a sexual medicine specialist can evaluate and prescribe without additional gatekeeping. PAs must maintain a collaborative relationship with a supervising physician, but the PA can still write the Vyleesi prescription directly.

Lab Work and Clinical Screening Before Prescribing

No single lab panel is FDA-mandated before initiating bremelanotide, but most prescribers order baseline bloodwork to exclude organic causes of low desire that mimic HSDD.

A standard pre-Vyleesi workup in DC typically includes thyroid-stimulating hormone (TSH), free thyroxine (free T4), prolactin, total and free testosterone, estradiol, DHEA-S, a comprehensive metabolic panel, and a complete blood count. Elevated prolactin from a pituitary adenoma, untreated hypothyroidism, or profoundly low estradiol can each suppress desire independently, and treating the underlying condition may resolve symptoms without bremelanotide.

The American College of Obstetricians and Gynecologists (ACOG) recommends screening for depression, anxiety, and relationship distress as well, because psychological factors frequently coexist with or fully account for low desire [4]. A Patient Health Questionnaire-9 (PHQ-9) score above 10 warrants evaluation for major depressive disorder before attributing symptoms to HSDD.

Blood pressure should also be documented. The FDA label carries a precaution about transient increases in systolic blood pressure (mean increase of 2 to 3 mmHg) following each dose [2]. Women with uncontrolled hypertension or known cardiovascular disease should have those conditions stabilized before starting bremelanotide.

DC Medicaid and Insurance Coverage

DC Medicaid lists Vyleesi on its formulary with a prior authorization (PA) requirement. Commercial insurers in the District vary, but most large plans (CareFirst BlueCross BlueShield, Aetna, UnitedHealthcare) require PA as well.

A successful PA submission generally needs the following documentation: a confirmed HSDD diagnosis using ICD-10 code F52.0, evidence that the patient is premenopausal, documentation that at least one nonpharmacologic intervention was considered, lab results ruling out hormonal or thyroid-related causes, and the prescriber's clinical rationale for bremelanotide over alternatives.

Turnaround time for PA decisions in DC is governed by the DC Department of Health Care Finance regulations: standard requests must be adjudicated within 72 hours, and urgent requests within 24 hours. If the PA is denied, you have the right to appeal. The prescriber can file a peer-to-peer review with the insurer's medical director, which overturns roughly 40% to 60% of initial denials in sexual medicine cases according to published payer data.

For patients without insurance or with a coverage denial, manufacturer savings programs and 503A compounding (discussed below) can reduce out-of-pocket cost significantly. Brand-name Vyleesi carries a list price near $950 for a package of four autoinjectors.

Pharmacy Options: Retail, Specialty, and 503A Compounding

DC residents have three pharmacy channels for bremelanotide.

Retail specialty pharmacies stock brand-name Vyleesi autoinjectors. CVS Specialty, Accredo, and AllianceRx Walgreens Prime all serve DC addresses. These pharmacies handle the PA process on your behalf in many cases and ship temperature-controlled packages directly to your home.

503A compounding pharmacies in the District of Columbia are licensed to compound bremelanotide for individual patient prescriptions. A compounded formulation may cost $100 to $250 per month depending on dose count, compared to the brand-name price. The compound is prepared as a sterile subcutaneous injection, and the pharmacy must hold a DC Board of Pharmacy compounding license. Ask your prescriber to specify "compounded bremelanotide 1.75 mg/0.3 mL subcutaneous injection" on the prescription if you prefer this route.

Out-of-state 503A pharmacies can legally ship compounded bremelanotide into DC as long as the pharmacy holds a nonresident pharmacy license issued by the DC Board of Pharmacy and the prescription is patient-specific. Verify the pharmacy's DC nonresident license number before filling.

Timeline: Prescription to First Dose

The path from initial consultation to self-administering your first dose of bremelanotide in DC typically spans 5 to 10 business days. Here is a realistic breakdown.

Day 1: Telehealth or in-person visit. The prescriber evaluates symptoms, orders labs if not already completed, and makes the HSDD diagnosis. Day 2 to 3: Lab results return (most DC-area labs, including Quest and Labcorp locations in the District, offer next-day results for hormone panels). Day 3 to 4: The prescriber reviews labs, confirms the treatment plan, and sends the electronic prescription to your pharmacy. Day 4 to 8: The pharmacy initiates PA if required. Standard PA adjudication completes within 72 hours. Day 7 to 10: The pharmacy ships or dispenses the medication. Specialty pharmacies typically ship overnight with cold-chain packaging.

If you use a compounding pharmacy and your insurer does not require PA for compounded medications, the timeline shortens to roughly 5 to 7 business days. Women who arrive at the initial visit with recent lab work (drawn within the prior 60 days) can often receive the prescription the same day.

Self-Injection Technique and Dosing

Vyleesi is delivered as a 1.75 mg subcutaneous injection using a prefilled autoinjector (brand) or a standard insulin syringe with a compounded vial. The injection site is the abdomen or anterior thigh. Rotate sites to minimize local reactions.

Administer the dose at least 45 minutes before anticipated sexual activity. The most common side effects in the RECONNECT trials were nausea (40.0% vs. 1.3% placebo), flushing (20.3%), injection site reactions (5.4%), and headache (11.3%) [1]. Nausea tends to diminish with repeated use: by the third month, the percentage of women reporting moderate-to-severe nausea dropped by roughly half compared to the first month of dosing [2].

The FDA label limits use to no more than one dose in 24 hours and no more than 8 doses in a calendar month. There are no published data supporting higher frequency, and exceeding these limits has not been studied for safety.

A practical tip from clinical practice: taking an antiemetic such as ondansetron 4 mg orally 30 minutes before the bremelanotide injection can reduce first-dose nausea substantially. This off-label strategy is not in the package insert but is widely used among sexual medicine specialists, per a 2021 consensus review in the Journal of Sexual Medicine [5].

Bremelanotide vs. Flibanserin: Choosing in DC

Both bremelanotide and flibanserin (Addyi) are FDA-approved for premenopausal HSDD, but they differ in mechanism, route, and side-effect profile.

Flibanserin is a daily oral tablet that modulates serotonin (5-HT1A agonist, 5-HT2A antagonist). It requires continuous daily dosing for 4 to 8 weeks before efficacy can be assessed. Alcohol is contraindicated within 2 hours of dosing due to risk of severe hypotension and syncope. In the APPROVES trial (N=949), flibanserin increased satisfying sexual events by 0.5 to 1.0 per month over placebo [6].

Bremelanotide, by contrast, works on-demand. There is no alcohol restriction. The trade-off is the injection route and the high initial nausea rate. For women who prefer not to commit to daily dosing or who drink socially, bremelanotide may be the more practical option. For women who dislike injections or who have consistent, predictable patterns of desire impairment, daily flibanserin can be appropriate.

Both drugs are available through DC telehealth providers. Your prescriber can discuss which profile aligns better with your lifestyle and symptom pattern.

Transferring a Vyleesi Prescription to DC

If you hold an active bremelanotide prescription from another state and move to or begin residing in DC, your existing prescription can be transferred to a DC-licensed pharmacy under standard interstate prescription transfer rules. The receiving pharmacy contacts the dispensing pharmacy, verifies the prescription, and transfers the remaining refills.

For controlled-substance transfers, additional DEA rules apply, but bremelanotide is not a scheduled controlled substance, so the transfer process is straightforward. Compounded prescriptions cannot be transferred between pharmacies; your prescriber must write a new prescription to the DC compounding pharmacy.

If your prescriber is not licensed in DC, you will need a new evaluation from a DC-licensed provider before a new prescription can be issued. Telehealth makes this simple: many platforms can schedule a new-patient HSDD evaluation within 48 hours.

Safety Monitoring and Follow-Up

After starting bremelanotide, schedule a follow-up at 4 to 8 weeks to assess response and tolerability. The prescriber should re-administer the FSDS-DAO or an equivalent distress measure to quantify improvement. A 2-point reduction in distress score is considered clinically meaningful [1].

Blood pressure monitoring is recommended at follow-up visits. The FDA label notes that bremelanotide caused a mean transient increase of 3 mmHg systolic and 1.5 mmHg diastolic within 2 to 3 hours of injection, returning to baseline within 12 hours [2]. Women with hypertension should track home blood pressure readings on dosing days.

Skin hyperpigmentation has been reported with repeated use, particularly in women with darker skin tones. The mechanism involves melanocortin-1 receptor activation. In the RECONNECT trials, focal hyperpigmentation of the face, gingiva, or breasts occurred in approximately 1% of patients and was generally reversible after discontinuation [1].

Bremelanotide is pregnancy Category X. A pregnancy test is standard before initiation, and reliable contraception must be used throughout treatment.